Charles River Laboratories (CRL) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Total Cash From Operating Activities Chart for Charles River Laboratories
Charles River Laboratories (CRL) operating cash flow for FY2025 was USD 737.6M, a 0.4% change from FY2024. Charles River Laboratories's operating cash flow grew from USD 37.4M in 1998 to USD 737.6M in 2025 (1873.4% over 27 years). Operating cash flow compound annual growth rate: 5-year CAGR of 6.2%, 10-year CAGR of 9.9%, 20-year CAGR of 5.8%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $12.68B
- Implied Share Price
- $265.51
- Enterprise Value
- $14.14B
- Revenue (TTM)
- $4.00B
- EBITDA
- $836.13M
- Profit Margin
- -5.96%
- Trailing P/E
- —
- Forward P/E
- 21.05
- Price/Book (MRQ)
- 3.83
- Price/Sales (TTM)
- 3.20
- EV/EBITDA
- 48.67
- EV/Revenue
- 3.51
- Dividend Yield
- —
- Book Value
- $64.30
- Free Cash Flow (FY2025)
- $518.49M
- Free Cash Flow Yield
- 4.09%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.